1014 Hamilton Court
Menlo Park, CA 94025
Welcome to Scrip
Create an account to read this article
Already a subscriber?
Anosys Inc.
As a former head of discovery research at Rhone-Poulenc Rorer Inc. (now Aventis SA), Jean-Bernard Le Pecq, PhD was accustomed to learning of new discoveries on a regular basis. But in 1997, one particular breakthrough in cell-to-cell communications caught his attention. Researchers found that small vesicles, known as exosomes, allow for the transfer of proteins to other cells. Le Pecq believed that exosomes could be used as a mechanism to develop innovative therapeutic vaccines and this idea ultimately propelled him to co-found Anosys Inc. in 1997.
More from Strategy
• By
The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.
• By
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
• By
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
• By
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
More from Business
• By
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
• By
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
• By
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.